Drug class
Antiviral monoclonal antibodies for Zaire ebolavirus are a specialized drug class consisting of recombinant human monoclonal antibodies designed to treat infection caused by *Zaire ebolavirus*. Read more about Antiviral Monoclonal Antibodies - Zaire Ebola Virus
2 drugs in this class 2 manufacturers
Antiviral monoclonal antibodies for Zaire ebolavirus are a specialized drug class consisting of recombinant human monoclonal antibodies designed to treat infection caused by *Zaire ebolavirus*.
Members of this class—including ansuvimab as monotherapy and the multi-antibody cocktail of atoltivimab, maftivimab, and odesivimab—specifically bind to distinct epitopes on the surface glycoprotein of the virus.
By binding the viral glycoprotein, they prevent host-cell attachment, inhibit viral entry and membrane fusion, and can recruit host immune effector functions to neutralize circulating virions.
This therapeutic class is primarily indicated to reduce mortality in adult and pediatric patients with confirmed Ebola virus disease.
Antiviral monoclonal antibodies for Zaire ebolavirus are a specialized drug class consisting of recombinant human monoclonal antibodies designed to treat infection caused by *Zaire ebolavirus* This therapeutic class is primarily indicated to reduce mortality in adult and pediatric patients with confirmed Ebola virus disease
Antiviral monoclonal antibodies for Zaire ebolavirus are a specialized drug class consisting of recombinant human monoclonal antibodies designed to treat infection caused by *Zaire ebolavirus* This therapeutic class is primarily indicated to reduce mortality in adult and pediatric patients with confirmed Ebola virus disease
Members of this class—including ansuvimab as monotherapy and the multi-antibody cocktail of atoltivimab, maftivimab, and odesivimab—specifically bind to distinct epitopes on the surface glycoprotein of the virus
Members of this class—including ansuvimab as monotherapy and the multi-antibody cocktail of atoltivimab, maftivimab, and odesivimab—specifically bind to distinct epitopes on the surface glycoprotein of the virus By binding the viral glycoprotein, they prevent host-cell attachment, inhibit viral entry and membrane fusion, and can recruit host immune effector functions to neutralize circulating virions
Members of this class—including ansuvimab as monotherapy and the multi-antibody cocktail of atoltivimab, maftivimab, and odesivimab—specifically bind to distinct epitopes on the surface glycoprotein of the virus By binding the viral glycoprotein, they prevent host-cell attachment, inhibit viral entry and membrane fusion, and can recruit host immune effector functions to neutralize circulating virions
By binding the viral glycoprotein, they prevent host-cell attachment, inhibit viral entry and membrane fusion, and can recruit host immune effector functions to neutralize circulating virions
This therapeutic class is primarily indicated to reduce mortality in adult and pediatric patients with confirmed Ebola virus disease
Following a drug class requires a free Physicians Office Resource account.
